UBS AM
ALT icon

UBS AM’s Altimmune ALT Stock Holding History

UBS AM’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.8K Buy
4,154
+3,482
+518% +$14.8K ﹤0.01% 3247
2025
Q4 		$2.43K Buy
+672
New +$2.93K ﹤0.01% 3104
2025
Q3 		– Sell
-4,215
Closed -$16.3K – 2284
2025
Q2 		$16.3K Sell
4,215
-102,657
-96% -$556K ﹤0.01% 2612
2025
Q1 		$534K Buy
106,872
+14,480
+16% +$91.7K ﹤0.01% 2487
2024
Q4 		$666K Buy
92,392
+13,126
+17% +$100K ﹤0.01% 2502
2024
Q3 		$487K Sell
79,266
-25,916
-25% -$176K ﹤0.01% 2651
2024
Q2 		$699K Buy
105,182
+86,982
+478% +$642K ﹤0.01% 2531
2024
Q1 		$185K Buy
+18,200
New +$185K ﹤0.01% 2471
2023
Q3 		– Sell
-19,200
Closed -$81K – 2590
2023
Q2 		$81K Hold
19,200
– – ﹤0.01% 2651
2023
Q1 		$81K Sell
19,200
-35,500
-65% -$422K ﹤0.01% 2651
2022
Q4 		$900K Buy
+54,700
New +$614K ﹤0.01% 1900

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

UBS AM's ALT Position: Q1 2026 in Review

UBS AM increased its Altimmune (ALT) stake by 518% in Q1 2026, buying an estimated $14.8K and bringing the position to 4,154 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3247.

UBS AM first reported a position in ALT in Q4 2022 and has held it in 11 quarters since. The position peaked at $900K in Q4 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • UBS AM held 4,154 shares of Altimmune worth $12.8K as of Q1 2026.
  • UBS AM bought 3,482 Altimmune shares in Q1 2026, an estimated $14.8K.
  • Altimmune made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #3247 holding.
  • UBS AM first reported a position in Altimmune in Q4 2022 and has held it in 11 quarters since.
  • UBS AM's Altimmune position peaked at $900K in Q4 2022.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.